



- a company developing evidence-based treatments - specifically for children

Newsletter #6 - Mar 2022

A complete team in place

During recent months Cessatech, as part of our business progress, have advanced our leadership team, adding important competencies within CMC, Clinical, Regulatory and Business Development in order to progress and secure the full potential of our key asset CT001

Martin has from 14 years CMC with Lundbeck, Etienne a long history with Business Development from Leo Pharma and Nycomed, Louise from from both regulatory consultancy and Orphazyme, and Benedikte with clinical experience from both Novo Nordisk and Zealand Pharma
Probably the best small biotech team in the world...



Trial 0204 results (and 0206 progress)

Early March Cessatech reported positive outcome of our bioavailability trial 0204. The primary aim to investigate drug exposure relative to IV injection of the approved counterparts was successful, and the trial confirmed the primary endpoint of showing clinical relevant expose. In addition, CT001 was assessed to be safe and well-tolerated.



Additionally, we have seen very good progress with trial 0206 (pharmacokinetic trial in children), and we hope to have last patient last visit during the month of April or May. We will announce expected data results once we have last patient enrolled. The pivotal trial 0205 is expected to commence within Q2, as we are still waiting for ethics committee approval.

Annual report and Annual general meeting

The annual report was approved during AGM 17 March 2022, in addition Rachel Curtis Gravesen (former head of communications at Genmab for more than 8 years) was elected to the board of directors, and Martin Olin appointed vice chairman.

The (incentive) warrant program for key employees and management was continued, and the option of warrant (shares) was authorized, at a normal share price of DKK 0.20 (the same as today 1:1 for shares), but the warrant price still remains to be determined (normally an average of a defined period). This should hopefully clarify any misunderstanding.



The journey continues....

We continue to deliver according to our plans, on our very promising asset (CT001), although the biotech sector have experienced stock market headwinds lately. The fundamentals behind our company have not changed. Once we have a more stable market, we will slowly increase our investor relation activities.



The year 2022 will be very interesting for the company...